Psilocybin for Alzheimer's Disease
Also known as: Psilocin (active metabolite)
Psilocybin's neuroplasticity effects — BDNF upregulation and enhanced connectivity — may counteract the synaptic loss central to Alzheimer's.
Mechanism of Action
In Alzheimer's context, psilocybin-induced 5-HT2A activation promotes BDNF expression, stimulates dendritic spine growth, and enhances hippocampal neurogenesis. The anti-inflammatory effects (TNF-α reduction) and default mode network modulation may address both the neurobiological and cognitive network dysfunctions in AD.
General mechanism: Tryptamine psychedelic. 5-HT2A agonist. Induces BDNF, neuroplasticity, dendritic spine growth, default mode network dissolution.
Current Evidence
No Alzheimer's-specific clinical trials yet. The neuroplasticity mechanism is well-characterized. Observational reports suggest cognitive improvement, but controlled studies are needed. Microdosing protocols for cognitive enhancement are under investigation.
Clinical Status: No Alzheimer's trials. Neuroplasticity evidence from depression trials informs the rationale. Research interest growing.
Safety Profile
Physiologically safe. Psychological risks (anxiety, challenging experiences) require therapeutic setting. Contraindicated in psychosis history. Not addictive.
Key Research Questions
- Can psilocybin-induced neuroplasticity counteract Alzheimer's synaptic loss?
- Is microdosing or macrodosing more appropriate for cognitive benefit in AD?